GUA-08 - 375-miRNA expression and neoadjuvant therapy in high risk prostate cancer

Publication date: December 2019Source: European Urology Supplements, Volume 18, Issue 12Author(s): S.A. Reva, A.K. Nosov, M.V. Berkut, S.B. Petrov
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

Neoadjuvant Intense ADT for High Risk Prostate Cancer  (study page |release notes)
Source: dbGaP, the database of Genotypes and Phenotypes - Category: Genetics & Stem Cells Tags: StudyRelease Source Type: research
CONCLUSIONS: Developmentally reprogrammed PCa cell models recapitulate features of clinically-advanced prostate tumors including downregulated Rb1/p53 and overexpression of Sox2 with Sox9. Sox9 is a marker of a transitional state that identifies PCa cells under the stress of therapeutic assault and facilitates progression to therapy resistance. Its expression may index the relative activity of the NF-κB pathway. PMID: 31919137 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractPurposeHere, we re-checked the American Joint Committee on Cancer 7th edition subclassification and confirmed the possibility of percent tumor volume as a prognostic factor for biochemical recurrence in the 8th edition subclassification.MethodsA total of 1073 patients with pathologic T2 stage disease who underwent radical prostatectomy were included. Exclusion criteria were neoadjuvant therapy and pathologic T3 and N1 disease. Biochemical recurrence-free survival was estimated using the Kaplan –Meier method. Cox hazard regression was used to predict biochemical recurrence.ResultsAccording to the 7th edition s...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Prostate Cancer;   Chemotherapy Effect;   Hormone Sensitive Prostate Cancer;   Locally Advanced Prostate Carcinoma Interventions:   Drug: Neoadjuvant chemotherapy combined with hormone therapy;   Drug: Neoadjuvant hormone therapy;   Procedure: Radical Prostatectomy (RP)+ extended lymph node dissection Sponsor:   RenJi Hospital Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Patients with high-risk localized prostate cancer benefit from multimodality therapy of curative intent. Androgen-deprivation therapy (ADT) combined with radiation improves survival in this population. However, prior clinical trials of neoadjuvant ADT and surgery failed to consistently demonstrate a survival advantage. The development of novel, more potent hormonal agents presents an opportunity to revisit the potential for neoadjuvant therapy to improve long-term outcomes for patients with localized prostate cancer. We review recent advances in neoadjuvant approaches for prostate cancer and emerging clinical trials data s...
Source: The Cancer Journal - Category: Cancer & Oncology Tags: Review Articles Source Type: research
Publication date: Available online 18 December 2019Source: Academic RadiologyAuthor(s): Fiona M. Fennessy, Andriy Fedorov, Mark G. Vangel, Robert V. Mulkern, Maria Tretiakova, Rosina T. Lis, Clare Tempany, Mary-Ellen TaplinRationale and ObjectivesTo explore a role for multiparametric MRI (mpMRI) as a biomarker of response to neoadjuvant androgen deprivation therapy (ADT) for prostate cancer (PCa).Materials and MethodsThis prospective study was approved by the institutional review board and was HIPAA compliant. Eight patients with localized PCa had a baseline mpMRI, repeated after 6-months of ADT, followed by prostatectomy....
Source: Academic Radiology - Category: Radiology Source Type: research
ConclusionIMRT at a dose up to 78  Gy combined with short-term neoadjuvant ADT resulted in excellent long-term disease-free outcomes with acceptable morbidities among patients with IR PCa. In addition, the incidence of late recurrence was very low. Further investigation is warranted to confirm our findings.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Purpose of review Local treatment of the primary by either radical prostatectomy or radiation therapy is discussed controversially. The role of cytoreductive radical prostatectomy has been evaluated in few retrospective clinical studies but data of prospective randomized clinical phase-III trials are lacking. It is the purpose of this review to reflect the current knowledge on indication, functional and oncological outcomes of cytoreductive radical prostatectomy to objectively highlight what can be expected from this approach. Recent findings Cytoreductive radical prostatectomy (cRP) is associated with a long overall ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: SPECIAL COMMENTARIES Source Type: research
More News: Cancer | Cancer & Oncology | Neoadjuvant Therapy | Prostate Cancer | Urology & Nephrology